quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:00:59·97d
INSIDERFiling
Fate Therapeutics Inc. logo

President and CEO Valamehr Bahram was granted 335,000 shares, increasing direct ownership by 102% to 664,708 units (SEC Form 4)

FATE· Fate Therapeutics Inc.
Health Care
Original source

Companies

  • FATE
    Fate Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 31UpdateH.C. Wainwright$5.00
  • Oct 27UpdateWedbush$7.00
  • Nov 18UpdateBofA Securities-
  • Jun 17UpdatePiper Sandler$6.00
  • Mar 27UpdateWells Fargo$6.00
  • Jan 24UpdateH.C. Wainwright$7.00

Related

  • INSIDER5h
    Amendment: SEC Form 4 filed by Director Redmile Group, Llc
  • INSIDER1d
    SEC Form 4 filed by Redmile Group, Llc
  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.
  • PR7d
    Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting
  • PR14d
    Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
  • PR21d
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Fate Therapeutics Inc.
  • PR50d
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022